

QUARTERLY INVESTMENT REVIEW

Quality Investment Fund USD Class

Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
Quality Investment Fund USD Class (net)	8.21	6.78	10.35	18.65	16.11	14.28	13.62
Quality Investment Fund USD Class (gross)	8.34	7.05	10.93	19.28	16.74	14.92	14.26
MSCI World	11.47	9.47	16.26	18.30	14.55	10.66	10.33
Value Add vs. MSCI World	-3.27	-2.69	-5.91	+0.34	+1.56	+3.62	+3.29
S&P 500 (Net)	10.83	5.99	14.70	19.16	16.11	13.04	13.25
Value Add vs. S&P 500 (Net)	-2.62	+0.79	-4.35	-0.52	-0.00	+1.24	+0.37

Data Source: GMO

MAJOR PERFORMANCE DRIVERS

The Quality portfolio had a positive return this quarter, but performance trailed the S&P 500 and MSCI World indices. Generally we refrain from commenting on intra-quarter moves but the opening sentence does not begin to convey the drama and significance of recent stock market movements. For once, therefore, we will make an exception.

A precipitous decline hit global markets in the first days of the quarter as investors reacted to the “Liberation Day” imposition of tariffs on America’s friends and foes. Double-digit falls took the S&P 500 close to bear market territory, with the MSCI World not far behind. Quality likes chaos, at least in a relative sense, and the strategy held up about 3 percentage points better than the broader markets in the first week of the quarter. We have seen this relative behavior often in the past as market participants naturally gravitate toward the more conservative, higher quality businesses in moments of duress. At this point, the strategy was well ahead of the indices for 2025.

RISKS

Risks associated with investing in the Fund may include: (1) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; (2) Management and Operational Risk: the risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility; and (3) Focused Investment Risk: the Fund invests its assets in the securities of a limited number of issuers, and a decline in the market price of a particular security held by the Fund may affect the Fund's performance more than if the Fund invested in the securities of a larger number of issuers. For a more complete discussion of these and other risks, please consult the Fund's Prospectus.

Inception Date: 10-Nov-10

Performance Returns: Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit www.gmo.com. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.** Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. Gross of fees, expenses and transaction costs, if any. If these fees, expenses and costs were included, performance would be lower. A dilution adjustment may be applied on a subscription or redemption of shares to reflect the costs of dealing in the Fund's assets. The return on investment in the Fund may increase or decrease as a result of currency fluctuations if an investor's investment is made in a currency other than that used in the past performance calculation. If the Fund holds assets in currencies other than the base currency of the Fund and/or you invest in a share class that is denominated in a different currency than the base currency of the Fund, subject to any hedging at share class or Fund level, the value of your investment may be impacted by changes in the relative prices of the relevant currencies. The use of financial derivative instruments by the Fund may result in increased gains or losses within the Fund. The portfolio is actively-managed, is not managed relative to a benchmark and uses an index for performance comparison purposes only and, where applicable, to compute a performance fee.

QUARTERLY INVESTMENT REVIEW

MAJOR PERFORMANCE DRIVERS CONT.

Our approach to macro events is typically to navigate using the rear view mirror, i.e., by reacting rather than forecasting. Short-term macro events are hard to predict and even harder to invest ahead of (as what's already in the price is never telegraphed clearly). Instead, when there has been some sort of macro excitement, we look for opportunities to buy what is being put on sale. On this occasion, we took the opportunity to add to the racier "growth" part of the portfolio, which had been hit relatively hard, funded by a portion of more defensive positions in Consumer Staples and Health Care (alongside some of the more China-exposed names – contrarianism needs to be balanced with a consideration of where change might be longer lasting). The most significant purchase was in Broadcom. The company's stock had sold off alongside the semi-conductor AI businesses susceptible to market nerves and to tariffs – the latter was at least partially unwarranted as 40% of Broadcom's revenues derive from software.

Our intention was to continue to trade along these broad lines should the sell-off persist but the buying opportunity turned out to be short-lived. What followed was one of the most explosive rallies in modern stock market history. Returns were highest in AI, crypto, clean energy and other varieties of "risk on." The stock market rose by almost 25% in 11 weeks, the fastest retracement of a 15%+ sell-off in the S&P 500 in several decades. Broadcom was the best performing stock in the portfolio. Despite the positive contribution from trading, this was a challenging period for the strategy in a relative sense. The quid pro quo for the Quality Strategy's tendency to win in weak markets is a propensity to lose in raging markets and this was one for the books.

Consumer Staples and Health Care were notable laggards in terms of GICS sector returns. Of the two, Health Care was particularly impactful because it is not a monolithic exposure. The strategy's holdings here span the gamut of pharmaceuticals, managed care, diagnostics, medical devices, robotic surgery, and consumer health care. These health care positions lagged the rebound across the board. Pharmaceutical companies remain under the cloud of the political rhetoric, caught between tariff risk for overseas production (with manufacturing in low tax Ireland in focus) and the possibility of constrained drug pricing in the United States (or perhaps reduced sales outside of the United States if "most favoured nation" pricing sticks). The cloud is real but there is a building precedent for the administration to favor negotiated settlements; we expect that the demand for medical innovation to address unmet needs will remain an appropriately rewarded activity over time. Several of these names are well out of favor today.

U.S. managed health companies have been under pressure for some time now. Last quarter we published a white paper^[1] arguing that much of the bad press suffered by the sector reflects an incomplete picture of how the industry works, with other participants more heavily incentivised to shady practices than the managed care companies themselves. However, UnitedHealthcare added its own contribution to the malaise by delivering poor underwriting results associated with Medicare Advantage, an enhanced version of the government funded health care assistance for retirees. UnitedHealthcare's board reacted decisively with a change in CEO, reinstalling previous incumbent Steve Helmsley. We view this change as positive – Helmsley is a details guy and we expect operations to get sharper. The annual repricing of U.S. health insurance allows for a relatively speedy set of modifications to improve underwriting results. Furthermore, the company's stock trades at undemanding valuations and we suspect that even a modest improvement in operating trajectory could have an outsized, positive impact on the share price.

As the aphorism goes, markets climb a wall of worry. It seems perverse in some ways that markets can shrug off unresolved trade spats and an escalation of conflict in the Middle East, and yet excitement over the possibilities of technology continues afresh. The market has its mojo back for now. We believe that there are quality businesses available at attractive prices as a result and we continue our work to identify them, this quarter adding a new position in TradeWeb, which has winner-takes-most economics in some areas of fixed income trading. We expect a certain amount of noise going forward as markets process the risks and impacts of evolving trade and other policies on companies and on the economy. As ever, the strategy can offer participation in the fundamental returns of productive businesses with some market protection as events unfold.

Portfolio weights as a percent of equity for the securities mentioned are as follows: Broadcom (2.4%), United Healthcare (2.1%), and TradeWeb (0.6%).

[1] Don't Blame The Middleman – available at www.gmo.com

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The GMO Quality Investment Fund seeks to generate total return by investing primarily in equities the Focused Equity team believes to be of high quality.

The team believes that companies with established track records of historical profitability and strong fundamentals – high quality companies – are able to outgrow the average company over time and are therefore worth a premium price. The Fund's disciplined approach uses both quantitative and fundamental techniques to assess the relative quality and valuation of global companies and aims to exploit a long-term investment horizon while withstanding short-term volatility.

This is a marketing communication and a financial promotion. Past performance does not predict future returns.

IMPORTANT INFORMATION

This is a marketing communication and a financial promotion. This is not a contractually binding document. An investor should consider all of the Fund's characteristics including the investment objectives, risks, charges and expenses before investing. This and other important information can be found in the Fund's prospectus and the KIID/PRIIPs KID. To obtain a prospectus and the KIID/PRIIPs KID please visit www.gmo.com. Read the prospectus and the KIID/PRIIPs KID carefully before investing and do not base any final investment decision on this communication alone.

Comparator Index(es): The MSCI World Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. The S&P 500 (Net) Index is an independently maintained and widely published index comprised of U.S. large capitalization stocks. The return reflects the dividend reinvestment after the deduction of withholding tax. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third party licensors.

The Fund is a sub-fund of GMO Funds plc, an umbrella fund with segregated liability between sub-funds, which is authorised by the Central Bank of Ireland (the "Central Bank") as a UCITS pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended. The authorisation of GMO Funds plc is not an endorsement or guarantee of GMO Funds plc by the Central Bank. Neither the Central Bank nor the UK's Financial Conduct Authority has approved and or takes responsibility for the contents of this document or for the financial soundness of the Fund or for GMO Funds plc. GMO Funds plc is an EEA UCITS scheme which is recognised under Part 6 of The Collective Investment Schemes (Amendment etc.) (EU Exit) Regulations 2019, as amended.

GMO UK Limited Authorised and Regulated by the Financial Conduct Authority Registered no 4658801 England. GMO Netherlands is registered with the AFM.

The Fund has not been registered under the United States Investment Company Act of 1940, as amended, nor the U.S. Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly, in the U.S. or to any U.S. Person, unless the securities are registered under the Act or an exemption from the registration requirements of the Act is available. A U.S. Person is defined as (a) any individual who is a citizen or resident of the U.S. for federal income tax purposes; (b) a corporation, partnership, or other entity created or organized under the laws of or existing in the U.S.; (c) an estate or trust the income of which is subject to U.S. federal income tax regardless of whether such income is effectively connected with a U.S. trade or business.

Investors and potential investors can also obtain the prospectus and key investor information, and a summary of investor rights and information on access to collective redress mechanisms, in English and local languages where the Fund is registered, under the Literature section at the following website:

<https://www.gmo.com/europe/product-index-page/equities/quality-strategy/quality-investment-fund---dqf/>

Please note that the management company of the Fund may decide to terminate the arrangements made for the marketing of the Fund in one or more EU member states pursuant to the UCITS marketing passport in accordance with the procedure provided for under the applicable laws that implement Article 93a of Directive 2009/65/EC (the UCITS Directive).

A full list of fees and charges applied to investment can be found in the prospectus and in the KIID/PRIIPs KID, available at: <https://www.gmo.com/europe/product-index-page/equities/quality-strategy/quality-investment-fund---dqf/>

This advertisement has not been reviewed by the Monetary Authority of Singapore. The consolidated extract prospectus for Switzerland, key investor information document, annual and semi-annual reports, and articles of association can be obtained free of charge from the representative and paying agent in Switzerland, State Street International Bank GmbH, Munich, Zurich Branch, Kalandersplatz 5, 8027 Zürich. For private bank intermediaries in Singapore and Hong Kong, these materials are intended for institutional and Accredited/Professional Investors Use Only. UCITS HAVE NO GUARANTEED RETURN AND PAST PERFORMANCE DOES NOT GUARANTEE FUTURE PERFORMANCE. YOUR CAPITAL IS AT RISK.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office

www.GMO.com